Takeda has introduced a new digital tool designed to predict patient response to vedolizumab (Entyvio) in individuals with Crohn’s disease. The tool utilizes the VDZ-CDST scoring system, which evaluates five key clinical factors—previous intestinal surgeries, prior use of anti-TNFα therapies, history of fistulizing disease, baseline albumin levels, and C-reactive protein (CRP) levels. Based on this data, it generates a personalized probability score (low, intermediate, or high) for treatment response.
This AI-driven tool represents a breakthrough in precision medicine, allowing gastroenterologists to make more informed treatment decisions. By leveraging real-world and clinical trial data, it improves patient outcomes while optimizing the use of healthcare resources. Research has shown that patients with a high probability score are more likely to respond quickly, experience fewer complications, and require fewer hospitalizations.
Developed using data from pivotal clinical trials, including GEMINI 2 and Victory, the tool has demonstrated 92% sensitivity and 80% specificity in predicting treatment response. It was officially launched at Takeda’s Ikigai meeting in Madrid, where over 100 IBD specialists gathered to discuss the role of digital innovation and AI in improving patient care.
Article written by iSanidad Team
10/02/2025
Source:
iSanidasd